29 September 2022>: Clinical Research
Postoperative Dynamic of Leptin and Fibroblast Growth Factor 21 in 123 Patients Recovering from Cardiac Surgery
Da Liu 1BCE , Danyal Ghani 2BCE , Wilson Y. Szeto 3ABE , Krzysztof Laudanski 456ABCDEFG*DOI: 10.12659/MSM.937652
Med Sci Monit 2022; 28:e937652
Table 1 Demographics and clinical characteristics of the study sample.
Age, mean±SD [years] | 64.22±12.27 |
Sex – Male no. (% of total) | 93 (75.6%) |
BMI mean±SD [kg/m] | 28.4±5.99 |
Race (% Caucasian, % Black, % Asian, % Other) | 83.7%, 6.5%, 4.1%, 5.7% |
Duration of anesthesia; mean±SD [min] | 394.17±117.9 |
Duration of surgery; mean±SD [min] | 277.75±100.92 |
Coronary artery bypass surgery; no.* | 64 |
Mitral valvuloplasty & replacement; no.* | 16 |
Aortic valvuloplasty & replacement; no.* | 36 |
Others; no.* | 6 |
Estimated blood loss [ml] | 197.13±260.4 |
Total crystalloid during surgery [ml] | 1254.91±606.24 |
Corticosteroid administration (% of all cases) | 15.4% |
Ketorolac administration (% of all cases) | 7.4% |
Acetaminophen administration (% of all cases) | 71.3% |
ASA administration (% of all cases) | 66.4% |
APACHE score at 1 h, mean±SD | 17.08±6 |
APACHE score at 24 h, mean±SD | 9.95±5.17 |
APACHE score at 48 h, mean±SD | 9.33±4.99 |
CCI median (95% CI) | 4 (3.7–4.53) |
Acute Coronary Syndrome | 15.4% |
Chronic heart failure | 22% |
Connective tissue disease (non-active) | 15.4% |
Cerebrovascular disease | 9.8% |
Type 2 diabetes | 28.5% |
COPD | 6.5% |
Mortality | 1.6% |
CVA | 9.8% |
PE | 5.7% |
DVT | 8.9% |
AKI | 22.1% |
* Some patients had more than one procedure. |